Your browser doesn't support javascript.
SARS-CoV-2 infection and vaccination trigger long-lived B and CD4+ T lymphocytes with implications for booster strategies.
Mazzoni, Alessio; Vanni, Anna; Spinicci, Michele; Lamacchia, Giulia; Kiros, Seble Tekle; Rocca, Arianna; Capone, Manuela; Di Lauria, Nicoletta; Salvati, Lorenzo; Carnasciali, Alberto; Mantengoli, Elisabetta; Farahvachi, Parham; Zammarchi, Lorenzo; Lagi, Filippo; Colao, Maria Grazia; Liotta, Francesco; Cosmi, Lorenzo; Maggi, Laura; Bartoloni, Alessandro; Rossolini, Gian Maria; Annunziato, Francesco.
  • Mazzoni A; Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
  • Vanni A; Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
  • Spinicci M; Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
  • Lamacchia G; Infectious and Tropical Diseases Unit.
  • Kiros ST; Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
  • Rocca A; Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
  • Capone M; Infectious and Tropical Diseases Unit.
  • Di Lauria N; Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
  • Salvati L; Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
  • Carnasciali A; Infectious and Tropical Diseases Unit.
  • Mantengoli E; Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
  • Farahvachi P; Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
  • Zammarchi L; Infectious and Tropical Diseases Unit.
  • Lagi F; Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
  • Colao MG; Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
  • Liotta F; Infectious and Tropical Diseases Unit.
  • Cosmi L; Infectious and Tropical Diseases Unit.
  • Maggi L; Microbiology and Virology Unit.
  • Bartoloni A; Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
  • Rossolini GM; Immunology and Cell Therapy Unit, and.
  • Annunziato F; Flow Cytometry Diagnostic Center and Immunotherapy, Careggi University Hospital, Florence, Italy.
J Clin Invest ; 132(6)2022 03 15.
Article in English | MEDLINE | ID: covidwho-1685792
ABSTRACT
BACKGROUNDImmunization against SARS-CoV-2, the causative agent of COVID-19, occurs via natural infection or vaccination. However, it is currently unknown how long infection- or vaccination-induced immunological memory will last.METHODSWe performed a longitudinal evaluation of immunological memory to SARS-CoV-2 up to 1 year after infection and following mRNA vaccination in naive individuals and individuals recovered from COVID-19 infection.RESULTSWe found that memory cells are still detectable 8 months after vaccination, while antibody levels decline significantly, especially in naive individuals. We also found that a booster injection is efficacious in reactivating immunological memory to spike protein in naive individuals, whereas it was ineffective in previously SARS-CoV-2-infected individuals. Finally, we observed a similar kinetics of decay of humoral and cellular immunity to SARS-CoV-2 up to 1 year following natural infection in a cohort of unvaccinated individuals.CONCLUSIONShort-term persistence of humoral immunity, together with the reduced neutralization capacity versus the currently prevailing SARS-CoV-2 variants, may account for reinfections and breakthrough infections. Long-lived memory B and CD4+ T cells may protect from severe disease development. In naive individuals, a booster dose restored optimal anti-spike immunity, whereas the needs for vaccinated individuals who have recovered from COVID-19 have yet to be defined.FUNDINGThis study was supported by funds to the Department of Experimental and Clinical Medicine, University of Florence (Project Excellence Departments 2018-2022), the University of Florence (project RICTD2122), the Italian Ministry of Health (COVID-2020-12371849), and the region of Tuscany (TagSARS CoV 2).
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Vaccines / Variants Limits: Humans Language: English Year: 2022 Document Type: Article Affiliation country: JCI157990

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Vaccines / Variants Limits: Humans Language: English Year: 2022 Document Type: Article Affiliation country: JCI157990